Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuvectin in locally recurrent prostate cancer
NCT00005072Phase 2Terminated
- Sponsor
- Vical Incorporated
- Start
- Nov 2000
- Primary completion
- Apr 2003
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of Leuvectin in prostate cancer (PCa), sponsored by Vical Incorporated. Started Nov 2000; status: terminated.
02
Drugs
Leuvectin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005072.